Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085696 · ClinicalTrials.gov registry record · Phase 2
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
A Phase 2 study of Follicular Lymphoma and B-cell Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 13
- Study locations
NCT00085696 is a Phase 2 study of Follicular Lymphoma and B-cell Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 66 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (51% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT00085696, a Phase 2 study of Follicular Lymphoma and B-cell Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.
Conditions Studied
Interventions
- DRUG VELCADE and rituximab
Study Locations (13)
Georgia
- Emory University Cancer Institute, Winship Cancer Institute - Atlanta
- Georgia Cancer Specialists - Marietta
Illinois
- Rush University Medical Center - Chicago
- Midwest Cancer Research Group - Skokie
California
- UCLA School of Medicine - Los Angeles
Florida
- Florida Cancer Specialists - Fort Myers
Kansas
- Cancer Center of Kansas - Wichita
Missouri
- Oncology/Henmatology Associates of Kansas City - Kansas City
Ohio
- Mid Ohio Oncology/Hematology Inc. - Columbus
South Carolina
- Charleston Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085696
The ClinicalTrials.gov registry entry for NCT00085696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (51% lower). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which VELCADE and rituximab is the first listed.
NCT00085696 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Georgia, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00085696 about?
NCT00085696 is a clinical study titled "VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma". The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to...
What is the current status of trial NCT00085696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2004-05.
What conditions does trial NCT00085696 study?
This clinical trial studies the following conditions: Follicular Lymphoma, B-cell Lymphoma, Marginal Lymphoma.
What interventions are being tested in trial NCT00085696?
The interventions under investigation include: VELCADE and rituximab (DRUG).
Who is sponsoring clinical trial NCT00085696?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085696 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.